Mean fluorescence intensities of specific serum antibodies against various antigens

7
n fluorescence intensities of specific serum antibodies against various antigens Measurement of serum antibodies against various antigens before and during treatment. A bead-based assay was used for measuring specific serum antibodies. Beads of different color were coated with defined recombinant proteins and the binding of serum antibodies was measured and is given as median fluorescent intensity (MFI) of at least 100 beads per antigen. Significant increase or decrease of antibody titer was defined by at least two-fold change in MFI and is indicated by arrows. Green arrows delineate crossing of cut-off and thus show sero-conversions / sero-reversions. Most of the observed changes were titer increases (21 versus 5 decreases). Significant changes were observed mainly as fast titer change, i.e. between two consecutive blood draws. In four cases a gradually change in antibody titer was observed, where neighboring data points were not significant different, but distant ones were (marked by diagonal arrows). One example of a late and slow increase in antibody titer is seen in p16 antibody titer of patient #17. Most frequent antibody induction was found against p16. Specific high titer antibodies already before Serum antibodies against MAGE-A1 1 10 100 1000 10000 BL C1 C1 C2 C3 C4 BL C1 C2 C3 BL C1 BL C1 C2 C3 BL C1 BL C1 C2 C3 BL C1 BL C1 BL C1 BL C1 C2 C3 BL C1 C2 C3 C4 C5 C6 C7 C8 C9 BL C1 BL C1 BL C1 C2 C3 C4 C8 BL C1 C2 C4 BL C1 BL C1 C3 C8 BL C1 C2 C3 C4 BL C1 C2 C3 C4 C8 BL C2 C3 C4 C8 CL C1 C2 BL C1 C2 C3 C8 BL C1 C3 BL C1 C4 C8 BL C1 C2 C3 BL C1 C2 C8 BL C1 C2 C3 #01 #02 #03 #04 #05 #06 #08 #09#10#13 #16 #17 #18#20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39 Patient number and vaccination cycle MFI Legend for all graphs Median fluorescence intensity for specific antibody reactivity at the given treatment cycle Cut-off for given antigen #01 Patient number BL C1 C2 C3 C4 C8 Treatment cycle; BL = baseline MFI Median fluorescence intensity (logarithmic scale) Significant increase / decrease (> 2-fold; < 0.5-fold) between two measurements; values cross cut-off (sero-conversion or sero- reversion) Significant increase / decrease (> 2-fold; < 0.5-fold) between two measurements; both values above cut-off

description

Serum antibodies against MAGE-A1. 10000. 1000. MFI. 100. 10. 1. BL. C1. C1. C2. C3. C4. BL. C1. C2. C3. BL. C1. BL. C1. C2. C3. BL. C1. BL. C1. C2. C3. BL. C1. BL. C1. BL. C1. BL. C1. C2. C3. BL. C1. C2. C3. C4. C5. C6. C7. C8. C9. BL. C1. BL. C1. - PowerPoint PPT Presentation

Transcript of Mean fluorescence intensities of specific serum antibodies against various antigens

Page 1: Mean fluorescence intensities of specific serum antibodies against various antigens

Mean fluorescence intensities of specific serum antibodies against various antigens

Measurement of serum antibodies against various antigens before and during treatment.A bead-based assay was used for measuring specific serum antibodies. Beads of different color were coated with defined recombinant proteins and the binding of serum antibodies was measured and is given as median fluorescent intensity (MFI) of at least 100 beads per antigen. Significant increase or decrease of antibody titer was defined by at least two-fold change in MFI and is indicated by arrows. Green arrows delineate crossing of cut-off and thus show sero-conversions / sero-reversions. Most of the observed changes were titer increases (21 versus 5 decreases). Significant changes were observed mainly as fast titer change, i.e. between two consecutive blood draws. In four cases a gradually change in antibody titer was observed, where neighboring data points were not significant different, but distant ones were (marked by diagonal arrows). One example of a late and slow increase in antibody titer is seen in p16 antibody titer of patient #17. Most frequent antibody induction was found against p16. Specific high titer antibodies already before vaccination have been observed in 35 cases, 4 of which increased further (red arrows; MAGE-A1, A3, A9 and LAGE-1).

Serum antibodies against MAGE-A1

1

10

100

1000

10000B

LC

1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

MF

I

Legend for all graphs

Median fluorescence intensity for specific antibody reactivity at the given treatment cycle

Cut-off for given antigen

#01 Patient number

BL

C1

C2

C3

C4

C8 Treatment cycle; BL = baseline

MFI Median fluorescence intensity (logarithmic scale)

Significant increase / decrease (> 2-fold; < 0.5-fold) between two measurements; values cross cut-off (sero-conversion or sero-reversion)

Significant increase / decrease (> 2-fold; < 0.5-fold) between two measurements; both values above cut-off

Page 2: Mean fluorescence intensities of specific serum antibodies against various antigens

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Serum antibodies against MAGE-A9

1

10

100

1000

10000

MF

I

MAGE-A9 cut-off

Serum antibodies against MAGE-A3

1

10

100

1000

10000

MF

IMAGE-A3 cut-off

Page 3: Mean fluorescence intensities of specific serum antibodies against various antigens

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Serum antibodies against LAGE-1a

1

10

100

1000

10000

MF

ILAGE-1a cut-off

Serum antibodies against CAMEL

1

10

100

1000

10000

MF

I

CAMEL cut-off

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Page 4: Mean fluorescence intensities of specific serum antibodies against various antigens

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Serum antibodies against GAGE-7b

1

10

100

1000

10000

MF

IGAGE-7b cut-off

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Serum antibodies against se70-2

1

10

100

1000

10000

MF

I

se70-2 cut-off

Page 5: Mean fluorescence intensities of specific serum antibodies against various antigens

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Serum antibodies against se57-1

1

10

100

1000

10000

MF

Ise57-1 cut-off

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Serum antibodies against GBP5ta

1

10

100

1000

10000

MF

I

GPB5ta cut-off

Page 6: Mean fluorescence intensities of specific serum antibodies against various antigens

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Serum antibodies against cTAGE5a (N-terminus)

1

10

100

1000

10000

MF

IcTAGE5a (N) cut-off

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Serum antibodies against cTAGE5a (C-terminus)

1

10

100

1000

10000

MF

I

cTAGE5a (C) cut-off

Page 7: Mean fluorescence intensities of specific serum antibodies against various antigens

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Serum antibodies against p53

1

10

100

1000

10000

MF

Ip53 cut-off

BL

C1

C1

C2

C3

C4

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

C2

C3

BL

C1

BL

C1

BL

C1

BL

C1

C2

C3

BL

C1

C2

C3

C4

C5

C6

C7

C8

C9

BL

C1

BL

C1

BL

C1

C2

C3

C4

C8

BL

C1

C2

C4

BL

C1

BL

C1

C3

C8

BL

C1

C2

C3

C4

BL

C1

C2

C3

C4

C8

BL

C2

C3

C4

C8

CL

C1

C2

BL

C1

C2

C3

C8

BL

C1

C3

BL

C1

C4

C8

BL

C1

C2

C3

BL

C1

C2

C8

BL

C1

C2

C3

#01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39

Patient number and vaccination cycle

Serum antibodies against p16

1

10

100

1000

10000

MF

I

p16 cut-off


Antigens and Antibodies - University of Baghdadcodental.uobaghdad.edu.iq/.../04/Antigen-and-Antibodies-.pdf · closely related antigens. B. Secondary function: Effector Functions

Antigens and Antibodies - University of Baghdadcodental.uobaghdad.edu.iq/.../04/Antigen-and-Antibodies-.pdf · closely related antigens. B. Secondary function: Effector Functions

Antigens & Antibodies Imcb.berkeley.edu/courses/mcb150/lecture3/Lecture3(4).pdf · 2007. 1. 18. · Antigens & Antibodies I Discovery of antibodies Basic Antibody Structure brief

Antigens & Antibodies Imcb.berkeley.edu/courses/mcb150/lecture3/Lecture3(4).pdf · 2007. 1. 18. · Antigens & Antibodies I Discovery of antibodies Basic Antibody Structure brief

Antinuclear antibodies (ANA) Antibodies to extractable ... (… · An important group of antinuclear antibodies represent antibodies against ENA (extractable nuclear antigens: SS-A/Ro,

Antinuclear antibodies (ANA) Antibodies to extractable ... (… · An important group of antinuclear antibodies represent antibodies against ENA (extractable nuclear antigens: SS-A/Ro,

Antigens and Antibodies. Antibodies Antigens Antigen: A substance that can be recognized by the adaptive arm of the immune system. Immunogen: Those antigens.

Antigens and Antibodies. Antibodies Antigens Antigen: A substance that can be recognized by the adaptive arm of the immune system. Immunogen: Those antigens.

Identification of Antibodies to Red Cell Antigens - Final

Identification of Antibodies to Red Cell Antigens - Final

Topic (7): Antibodies and Antigens - Doctor 2016...antigens [Ags] (the other two are T-cell receptor [TCR] and major histocompatibility complex [MHC]) {Figure 1}. Antibodies have a

Topic (7): Antibodies and Antigens - Doctor 2016...antigens [Ags] (the other two are T-cell receptor [TCR] and major histocompatibility complex [MHC]) {Figure 1}. Antibodies have a

Vaccine-induced antibodies target sequestered viral antigens to … · 2020. 7. 13. · ARTICLE OPEN Vaccine-induced antibodies target sequestered viral antigens to prevent ocular

Vaccine-induced antibodies target sequestered viral antigens to … · 2020. 7. 13. · ARTICLE OPEN Vaccine-induced antibodies target sequestered viral antigens to prevent ocular

Antigens, Antibodies and Their Interactions

Antigens, Antibodies and Their Interactions

Blood Group Antigens and Antibodies - New York Blood …nybloodcenter.org/media/filer_public/2016/04/11/vivien_powell... · HOSPITAL/INSTITUTE/CENTER Blood Group Antigens and Antibodies

Blood Group Antigens and Antibodies - New York Blood …nybloodcenter.org/media/filer_public/2016/04/11/vivien_powell... · HOSPITAL/INSTITUTE/CENTER Blood Group Antigens and Antibodies

ANTIBODIES ANTIGENS · MONOCLONAL ANTIBODIES Polyclonal antibodies, from sheep or rabbit, have been widely used from the 90s, in Immunoassays. While polyclonal antibodies are simple

ANTIBODIES ANTIGENS · MONOCLONAL ANTIBODIES Polyclonal antibodies, from sheep or rabbit, have been widely used from the 90s, in Immunoassays. While polyclonal antibodies are simple

Blood Group Antigens and Antibodies - New York … Group Antigens and Antibodies 2 Blood Group Antigens and Antibodies • Blood Group Immunology/ •Pre-transfusion Testing • ABO

Blood Group Antigens and Antibodies - New York … Group Antigens and Antibodies 2 Blood Group Antigens and Antibodies • Blood Group Immunology/ •Pre-transfusion Testing • ABO

Chapter 3 Antigens and Antibodies and T cell receptors Dr. Capers.

Chapter 3 Antigens and Antibodies and T cell receptors Dr. Capers.

Antigens and antibodies rlo with hyperlink to video and no audio

Antigens and antibodies rlo with hyperlink to video and no audio

Antigens & Antibodies II Polyclonal antibodies vs …...3 Cross-reactive Antigens Antigens & Antibodies II Definitions and comparison of B and T cell antigen recognition Quantitating

Antigens & Antibodies II Polyclonal antibodies vs …...3 Cross-reactive Antigens Antigens & Antibodies II Definitions and comparison of B and T cell antigen recognition Quantitating

Efficient generation of monoclonal antibodies against ...€¦ · Monoclonal antibodies specific for foreign antigens, auto-antigens, allogeneic antigens and tumour neo-antigens

Efficient generation of monoclonal antibodies against ...€¦ · Monoclonal antibodies specific for foreign antigens, auto-antigens, allogeneic antigens and tumour neo-antigens

Introduction Primary Antibodies & Antigens · Primary Antibodies & Antigens e-mail interbiotech@interchim.com Visit our website : ! Interchim provides more than 20 000 primary antibodies

Introduction Primary Antibodies & Antigens · Primary Antibodies & Antigens e-mail [email protected] Visit our website : ! Interchim provides more than 20 000 primary antibodies

When Tissue Antigens and Antibodies Get Along

When Tissue Antigens and Antibodies Get Along

MONOCLONAL ANTIBODIES TO GUINEA PIG Ia ANTIGENS · MONOCLONAL ANTIBODIES TO GUINEA PIG Ia ANTIGENS II. Effect on Alloantigen-, Antigen-, and Mitogen-induced ... LNL, enriched column-purified

MONOCLONAL ANTIBODIES TO GUINEA PIG Ia ANTIGENS · MONOCLONAL ANTIBODIES TO GUINEA PIG Ia ANTIGENS II. Effect on Alloantigen-, Antigen-, and Mitogen-induced ... LNL, enriched column-purified

Chapter 4 Antigens and Antibodies Dr. Capers. Kuby IMMUNOLOGY Sixth Edition Chapter 4 Antigens and Antibodies Copyright © 2007 by W. H. Freeman and Company.

Chapter 4 Antigens and Antibodies Dr. Capers. Kuby IMMUNOLOGY Sixth Edition Chapter 4 Antigens and Antibodies Copyright © 2007 by W. H. Freeman and Company.

Measurement of Immune function:. Detect antigens and / or antibodies. Immunological tests rely upon: ability of antibodies to aggregate particulate antigens.

Measurement of Immune function:. Detect antigens and / or antibodies. Immunological tests rely upon: ability of antibodies to aggregate particulate antigens.